Department of Pharmacology (National Key Laboratory of Frigid Zone Cardiovascular Diseases, the State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin 150081, China
Cardiac fibrosis caused by ventricular remodeling and dysfunction such as post-myocardial infarction (MI) can lead to heart failure. RNA N6-methyladenosine (m6A) methylation has been shown to play a pivotal role in the occurrence and development of many illnesses. In investigating the biological function of the m6A reader YTHDF1 in cardiac fibrosis, adeno-associated virus 9 was used to knock down or overexpress the YTHDF1 gene in mouse hearts, and MI surgery in vivo and transforming growth factor-β (TGF-β)-activated cardiac fibroblasts in vitro were performed to establish fibrosis models. Our results demonstrated that silencing YTHDF1 in mouse hearts can significantly restore impaired cardiac function and attenuate myocardial fibrosis, whereas YTHDF1 overexpression could further enhance cardiac dysfunction and aggravate the occurrence of ventricular pathological remodeling and fibrotic development. Mechanistically, zinc finger BED-type containing 6 mediated the transcriptional function of the YTHDF1 gene promoter. YTHDF1 augmented AXL translation and activated the TGF-β-Smad2/3 signaling pathway, thereby aggravating the occurrence and development of cardiac dysfunction and myocardial fibrosis. Consistently, our data indicated that YTHDF1 was involved in activation, proliferation, and migration to participate in cardiac fibrosis in vitro. Our results revealed that YTHDF1 could serve as a potential therapeutic target for myocardial fibrosis.
V Castiglione, A Aimo, G Vergaro, L Saccaro, C Passino, M Emdin. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev 2022; 27(2): 625–643 https://doi.org/10.1007/s10741-021-10105-w
A González, EB Schelbert, J Díez, J Butler. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J Am Coll Cardiol 2018; 71(15): 1696–1706 https://doi.org/10.1016/j.jacc.2018.02.021
4
PS Azevedo, BF Polegato, MF Minicucci, SA Paiva, LA Zornoff. Cardiac remodeling: concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment. Arq Bras Cardiol 2016; 106(1): 62–69 https://doi.org/10.5935/abc.20160005
5
RM Burke, JK Lighthouse, DM Mickelsen, EM Small. Sacubitril/valsartan decreases cardiac fibrosis in left ventricle pressure overload by restoring PKG signaling in cardiac fibroblasts. Circ Heart Fail 2019; 12(4): e005565 https://doi.org/10.1161/CIRCHEARTFAILURE.118.005565
6
SA Su, D Yang, Y Wu, Y Xie, W Zhu, Z Cai, J Shen, Z Fu, Y Wang, L Jia, Y Wang, JA Wang, M Xiang. EphrinB2 regulates cardiac fibrosis through modulating the interaction of Stat3 and TGF-β/Smad3 signaling. Circ Res 2017; 121(6): 617–627 https://doi.org/10.1161/CIRCRESAHA.117.311045
M Luo, H Peng, P Chen, Y Zhou. The immunomodulatory role of interleukin-35 in fibrotic diseases. Expert Rev Clin Immunol 2019; 15(4): 431–439 https://doi.org/10.1080/1744666X.2019.1564041
H Shah, A Hacker, D Langburt, M Dewar, MJ McFadden, H Zhang, U Kuzmanov, YQ Zhou, B Hussain, F Ehsan, B Hinz, AO Gramolini, SP Heximer. Myocardial infarction induces cardiac fibroblast transformation within injured and noninjured regions of the mouse heart. J Proteome Res 2021; 20(5): 2867–2881 https://doi.org/10.1021/acs.jproteome.1c00098
11
LJ Deng, WQ Deng, SR Fan, MF Chen, M Qi, WY Lyu, Q Qi, AK Tiwari, JX Chen, DM Zhang, ZS Chen. m6A modification: recent advances, anticancer targeted drug discovery and beyond. Mol Cancer 2022; 21(1): 52 https://doi.org/10.1186/s12943-022-01510-2
12
R Gong, X Wang, H Li, S Liu, Z Jiang, Y Zhao, Y Yu, Z Han, Y Yu, C Dong, S Li, B Xu, W Zhang, N Wang, X Li, X Gao, F Yang, D Bamba, W Ma, Y Liu, B Cai. Loss of m6A methyltransferase METTL3 promotes heart regeneration and repair after myocardial injury. Pharmacol Res 2021; 174: 105845 https://doi.org/10.1016/j.phrs.2021.105845
13
YS Chen, XP Ouyang, XH Yu, P Novák, L Zhou, PP He, K Yin. N6-adenosine methylation (m6A) RNA modification: an emerging role in cardiovascular diseases. J Cardiovasc Transl Res 2021; 14(5): 857–872 https://doi.org/10.1007/s12265-021-10108-w
14
X Wang, BS Zhao, IA Roundtree, Z Lu, D Han, H Ma, X Weng, K Chen, H Shi, C He. N6-methyladenosine modulates messenger RNA translation efficiency. Cell 2015; 161(6): 1388–1399 https://doi.org/10.1016/j.cell.2015.05.014
15
D Jin, J Guo, Y Wu, L Yang, X Wang, J Du, J Dai, W Chen, K Gong, S Miao, X Li, H Sun. m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC. Mol Cancer 2020; 19(1): 40 https://doi.org/10.1186/s12943-020-01161-1
16
L Liu, X Liu, Z Dong, J Li, Y Yu, X Chen, F Ren, G Cui, R Sun. N6-methyladenosine-related genomic targets are altered in breast cancer tissue and associated with poor survival. J Cancer 2019; 10(22): 5447–5459 https://doi.org/10.7150/jca.35053
17
N Okura, N Nishioka, T Yamada, H Taniguchi, K Tanimura, Y Katayama, A Yoshimura, S Watanabe, T Kikuchi, S Shiotsu, T Kitazaki, A Nishiyama, M Iwasaku, Y Kaneko, J Uchino, H Uehara, M Horinaka, T Sakai, K Tanaka, R Kozaki, S Yano, K Takayama. ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer. Clin Cancer Res 2020; 26(9): 2244–2256 https://doi.org/10.1158/1078-0432.CCR-19-2321
18
M Tanaka, DW Siemann. Therapeutic targeting of the Gas6/Axl signaling pathway in cancer. Int J Mol Sci 2021; 22(18): 9953 https://doi.org/10.3390/ijms22189953
19
L Quirico, F Orso, CL Esposito, S Bertone, R Coppo, L Conti, S Catuogno, F Cavallo, V de Franciscis, D Taverna. Axl-148b chimeric aptamers inhibit breast cancer and melanoma progression. Int J Biol Sci 2020; 16(7): 1238–1251 https://doi.org/10.7150/ijbs.39768
20
M Batlle, P Recarte-Pelz, E Roig, MA Castel, M Cardona, M Farrero, JT Ortiz, B Campos, MJ Pulgarín, J Ramírez, F Pérez-Villa, de Frutos P García. AXL receptor tyrosine kinase is increased in patients with heart failure. Int J Cardiol 2014; 173(3): 402–409 https://doi.org/10.1016/j.ijcard.2014.03.016
21
G Caldentey, De Frutos P García, H Cristóbal, M Garabito, A Berruezo, X Bosch, Antonio R San, E Flores-Umanzor, RJ Perea, Caralt TM De, J Rodríguez, JT Ortiz-Pérez. Serum levels of growth arrest-specific 6 protein and soluble AXL in patients with ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care 2019; 8(8): 708–716 https://doi.org/10.1177/2048872617740833
22
M DeBerge, K Glinton, M Subramanian, LD Wilsbacher, CV Rothlin, I Tabas, EB Thorp. Macrophage AXL receptor tyrosine kinase inflames the heart after reperfused myocardial infarction. J Clin Invest 2021; 131(6): e139576 https://doi.org/10.1172/JCI139576
23
TY Li, W Su, LL Li, XG Zhao, N Yang, JX Gai, X Lv, J Zhang, MQ Huang, Q Zhang, WH Ji, XY Song, YH Zhou, XL Li, HL Shan, HH Liang. Critical role of PAFR/YAP1 positive feedback loop in cardiac fibrosis. Acta Pharmacol Sin 2022; 43(11): 2862–2872 https://doi.org/10.1038/s41401-022-00903-9
24
JJ Xu, RJ Li, ZH Zhang, C Yang, SX Liu, YL Li, MW Chen, WW Wang, GY Zhang, G Song, ZR Huang. Loganin inhibits angiotensin II-induced cardiac hypertrophy through the JAK2/STAT3 and NF-κB signaling pathways. Front Pharmacol 2021; 12: 678886 https://doi.org/10.3389/fphar.2021.678886
MJ Goumans, P Ten Dijke. TGF-β signaling in control of cardiovascular function. Cold Spring Harb Perspect Biol 2018; 10(2): a022210 https://doi.org/10.1101/cshperspect.a022210
JX Zhu, W Ling, C Xue, Z Zhou, YS Zhang, C Yan, MP Wu. Higenamine attenuates cardiac fibroblast abstract and fibrosis via inhibition of TGF-β1/Smad signaling. Eur J Pharmacol 2021; 900: 174013 https://doi.org/10.1016/j.ejphar.2021.174013
31
L Tao, Y Wang, E Gao, H Zhang, Y Yuan, WB Lau, L Chan, WJ Koch, XL Ma. Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction. Circ Res 2010; 106(2): 409–417 https://doi.org/10.1161/CIRCRESAHA.109.211797
32
GL Huang, D Liao, H Chen, Y Lu, L Chen, H Li, B Li, W Liu, C Ye, T Li, Z Zhu, J Wang, T Uchida, Y Zou, Z Dong, Z He. The protein level and transcription activity of activating transcription factor 1 is regulated by prolyl isomerase Pin1 in nasopharyngeal carcinoma progression. Cell Death Dis 2016; 7(12): e2571 https://doi.org/10.1038/cddis.2016.349
33
FF Chen, FQ Song, YQ Chen, ZH Wang, YH Li, MH Liu, Y Li, M Song, W Zhang, J Zhao, M Zhong. Exogenous testosterone alleviates cardiac fibrosis and apoptosis via Gas6/Axl pathway in the senescent mice. Exp Gerontol 2019; 119: 128–137 https://doi.org/10.1016/j.exger.2019.01.029
34
HY Zhu, WD Bai, J Li, K Tao, HT Wang, XK Yang, JQ Liu, YC Wang, T He, ST Xie, DH Hu. Peroxisome proliferator-activated receptor-γ agonist troglitazone suppresses transforming growth factor-β1 signalling through miR-92b upregulation-inhibited Axl expression in human keloid fibroblasts in vitro. Am J Transl Res 2016; 8(8): 3460–3470
35
Q Zhang, L Wang, S Wang, H Cheng, L Xu, G Pei, Y Wang, C Fu, Y Jiang, C He, Q Wei. Signaling pathways and targeted therapy for myocardial infarction. Signal Transduct Target Ther 2022; 7(1): 78 https://doi.org/10.1038/s41392-022-00925-z
36
MM Gladka, A Kohela, B Molenaar, D Versteeg, L Kooijman, J Monshouwer-Kloots, V Kremer, HR Vos, MMH Huibers, JJ Haigh, D Huylebroeck, RA Boon, M Giacca, E van Rooij. Cardiomyocytes stimulate angiogenesis after ischemic injury in a ZEB2-dependent manner. Nat Commun 2021; 12(1): 84 https://doi.org/10.1038/s41467-020-20361-3
37
J Yang, K Savvatis, JS Kang, P Fan, H Zhong, K Schwartz, V Barry, A Mikels-Vigdal, S Karpinski, D Kornyeyev, J Adamkewicz, X Feng, Q Zhou, C Shang, P Kumar, D Phan, M Kasner, B López, J Diez, KC Wright, RL Kovacs, PS Chen, T Quertermous, V Smith, L Yao, C Tschöpe, CP Chang. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat Commun 2016; 7(1): 13710 https://doi.org/10.1038/ncomms13710
38
P Mathiyalagan, M Adamiak, J Mayourian, Y Sassi, Y Liang, N Agarwal, D Jha, S Zhang, E Kohlbrenner, E Chepurko, J Chen, MG Trivieri, R Singh, R Bouchareb, K Fish, K Ishikawa, D Lebeche, RJ Hajjar, S Sahoo. FTO-dependent N6-methyladenosine regulates cardiac function during remodeling and repair. Circulation 2019; 139(4): 518–532 https://doi.org/10.1161/CIRCULATIONAHA.118.033794
39
Ali M Akhtar, S Younis, O Wallerman, R Gupta, L Andersson, T Sjöblom. Transcriptional modulator ZBED6 affects cell cycle and growth of human colorectal cancer cells. Proc Natl Acad Sci USA 2015; 112(25): 7743–7748 https://doi.org/10.1073/pnas.1509193112
40
YZ Huang, LZ Zhang, XS Lai, MX Li, YJ Sun, CJ Li, XY Lan, CZ Lei, CL Zhang, X Zhao, H Chen. Transcription factor ZBED6 mediates IGF2 gene expression by regulating promoter activity and DNA methylation in myoblasts. Sci Rep 2014; 4(1): 4570 https://doi.org/10.1038/srep04570
41
L Jiang, O Wallerman, S Younis, CJ Rubin, ER Gilbert, E Sundström, A Ghazal, X Zhang, L Wang, TS Mikkelsen, G Andersson, L Andersson. ZBED6 modulates the transcription of myogenic genes in mouse myoblast cells. PLoS One 2014; 9(4): e94187 https://doi.org/10.1371/journal.pone.0094187
42
R Naboulsi, M Larsson, L Andersson, S Younis. ZBED6 regulates Igf2 expression partially through its regulation of miR483 expression. Sci Rep 2021; 11(1): 19484 https://doi.org/10.1038/s41598-021-98777-0
43
X Wu, X Liu, S Koul, CY Lee, Z Zhang, B Halmos. AXL kinase as a novel target for cancer therapy. Oncotarget 2014; 5(20): 9546–9563 https://doi.org/10.18632/oncotarget.2542
44
DC Yang, S Gu, JM Li, SW Hsu, SJ Chen, WH Chang, CH Chen. Targeting the AXL receptor in combating smoking-related pulmonary fibrosis. Am J Respir Cell Mol Biol 2021; 64(6): 734–746 https://doi.org/10.1165/rcmb.2020-0303OC
45
C Bárcena, M Stefanovic, A Tutusaus, L Joannas, A Menéndez, C García-Ruiz, P Sancho-Bru, M Marí, J Caballeria, CV Rothlin, JC Fernández-Checa, Frutos PG de, A Morales. Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation. J Hepatol 2015; 63(3): 670–678 https://doi.org/10.1016/j.jhep.2015.04.013
46
CA Steiner, ES Rodansky, LA Johnson, JA Berinstein, KC Cushing, S Huang, JR Spence, PDR Higgins. AXL is a potential target for the treatment of intestinal fibrosis. Inflamm Bowel Dis 2021; 27(3): 303–316 https://doi.org/10.1093/ibd/izaa169
47
TS Rigoni, NS Vellozo, K Guimarães-Pinto, M Cabral-Piccin, L Fabiano-Coelho, TC Matos-Silva, AA Filardy, CM Takiya, MF Lopes. Axl receptor induces efferocytosis, dampens M1 macrophage responses and promotes heart pathology in Trypanosoma cruzi infection. Commun Biol 2022; 5(1): 1421 https://doi.org/10.1038/s42003-022-04401-w
48
Z Ma, Q Li, P Liu, W Dong, Y Zuo. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP. Cell Biol Int 2020; 44(12): 2524–2531 https://doi.org/10.1002/cbin.11459
49
M Ikeuchi, H Tsutsui, T Shiomi, H Matsusaka, S Matsushima, J Wen, T Kubota, A Takeshita. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 2004; 64(3): 526–535 https://doi.org/10.1016/j.cardiores.2004.07.017
50
A Hanna, NG Frangogiannis. The role of the TGF-β superfamily in myocardial infarction. Front Cardiovasc Med 2019; 6: 140 https://doi.org/10.3389/fcvm.2019.00140
51
L Gao, LY Wang, ZQ Liu, D Jiang, SY Wu, YQ Guo, HM Tao, M Sun, LN You, S Qin, XC Cheng, JS Xie, GL Chang, DY Zhang. TNAP inhibition attenuates cardiac fibrosis induced by myocardial infarction through deactivating TGF-β1/Smads and activating P53 signaling pathways. Cell Death Dis 2020; 11(1): 44 https://doi.org/10.1038/s41419-020-2243-4
52
AB Jaykumar, S Plumber, DM Barry, D Binns, C Wichaidit, M Grzemska, S Earnest, EJ Goldsmith, O Cleaver, MH Cobb. WNK1 collaborates with TGF-β in endothelial cell junction turnover and angiogenesis. Proc Natl Acad Sci USA 2022; 119(30): e2203743119 https://doi.org/10.1073/pnas.2203743119
